Immune Regulation Ltd has appointed Jonathan Rigby as its chief executive and member of the board of directors. Formerly known as Peptinnovate, Immune Regulation is developing therapies for inflammatory and immunological diseases. Mr Rigby was previously CEO of SteadyMed Therapeutics Inc, leading the specialty pharma company to a listing on Nasdaq and sale to United Therapeutics Corp in 2018. Before that, he co-founded Zogenix Inc, another specialty pharma company focused on drugs for rare diseases.
Immune Regulation announced the appointment on 27 March 2020.
Copyright 2020 Evernow Publishing Ltd.